Development sub-sector medical glass

June 27, 2014 in Russia held a meeting StekloSouz plant managers, major manufacturers of medical glass for the pharmaceutical industry.

The Meeting discussed the current state and prospects of development of sub-sector production of medical glass products for the pharmaceutical industry, considered the Action Plan and other issues on the agenda of the meeting.Opening the meeting the president "StekloSouz" Osipov VI in his report spoke about the current state and prospects of development sub-sector.In 2012 Russia became a full member of the World Trade Organization.Domestic enterprises have shown significant activity caused by the need to introduce international standards of quality, above all GMP (Good Manufacturing Practice). Most major pharmaceutical companies have already switched to standard GMP. In addition, this postponement does not affect all types of products, and a very limited list of nomenclature.

At the same time there was an intensive renovation of equipment and high-tech production equipment automated lines great performance. International standards on products from Medsteklo harmonized with the technical specifications of imported equipment. As a result of sharply increased number of marriage using domestic products of medical glass, and some of the most advanced production lines simply refuse to work with them.

According to major pharmaceutical companies in Russia there is no production of high quality of glass (glass tubes medical), causing domestic enterprises produced from glass bottles have nonstandard geometric dimensions, do not allow for import nameplate capacity of packing machines and quality products in accordance with the requirements of GMP. As a result, a number of major pharmaceutical companies necessary for filling vials made of glass tube, currently purchases in China.

Same story with complex products produced from molten glass, especially glass bottles for blood transfusion and infusion drugs.

Actually go to the fact that the bulk of steklodrota and complex products to be imported from Medsteklo. It categorically does not meet the state policy in this sphere and national security requirements. Leadership of the country tasked maximize domestic production. The question of import is not only the military-industrial complex, but such an important sphere of life as drug manufacturing. If until 2008 the main goal of public policy in the field of development of the pharmaceutical and medical industry is saturated domestic market drugs and medical devices more simply overcoming the deficit, that then things began to change. To change this situation it was necessary corrections trends and public policy objectives in the field of medicines and medical devices in the direction of strengthening the role of domestic producers on the domestic market.

Prospects of development of sub-sector for the period 2020 yes actually defined by four strategic documents:

- Decree of the President of the Russian Federation dated May 7, 2012 № 598 "On improvement of public health policy";

- The development strategy of the pharmaceutical industry in the Russian Federation for the period up to 2020;

- Federal Target Program "Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and Beyond";

- State Program of the Russian Federation "Development of pharmaceutical and medical industries" for 2013 - 2020 years "(Government Decree of 15 April 2014);

These policies require the following outputs:

- Increase by 2020 to 50% share of domestic production of medicines in total consumption (in monetary terms);

- Increase by 2020 to 40% percent share of the domestic production of medical products in total consumption (in monetary terms);

- Increase in 2020 exports of pharmaceuticals and medical products to no less than 105 billion rubles.

In the Russian Ministry of Industry for these purposes created a new unit - the Department of the pharmaceutical and medical industries. To solve all these problems requires coordinated government action, "StekloSouz" Russia, factories - manufacturers of medical glass for the pharmaceutical industry, pharmaceutical unions and associations, large pharmaceutical companies and major suppliers of imported products.

The founders and managers of enterprises have adopted a number of important decisions required for the successful development of medical glass production in the current economic conditions.

Press-Center of StekloSouz 

600450 Development sub-sector medical glass
Date: 7 July 2014

See more news about:

Others also read

For overview analysis, the report introduces Fire Glass basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc   Browse Full Report With TOC @ international and China market analysis, the report analyzes Fire Glass markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different types and applications developments and trends of market, technology, and competitive landscape, and leading suppliers and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin.
Dubai Investments (DI) CEO Khalid Bin Kalban has revealed that the Company seeks to examine several expansion opportunities in 2015.
This report was created for strategic planners, international executives and import/export managers who are concerned with the market for nonwired glass sheets of float glass and surface ground or polished glass.
New Business to Support Company's Growing Presence in East and Central African Markets - H.B. Fuller Company (NYSE: FUL) announced today that it has signed an agreement to purchase Continental Products Limited, a provider of industrial adhesives in East and Central Africa.
"Opportunity in the Indian Glass Market - 2014 : Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast" provides an insight into the Indian Glass current market scenario, structure and practices.
Coinciding with the fulfillment of the ARTESUN project´s first year (November), the third Project Meeting took place at Corning headquarters in Avon, France    Funded by the European Comission through its Seventh Framework Programme, ARTESUN Project aims to develop organic photovoltaic solar cells (OPV) through the implementation of three full-scale prototypes.

Add new comment